Assetmark, Inc Iovance Biotherapeutics, Inc. Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 12,853 shares of IOVA stock, worth $119,147. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,853

Previous 8,686 47.97%

Holding current value

$119,147

Previous $69,000 73.91%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$7.28 - $11.9 $30,335 - $49,587	4,167 Added 47.97%	12,853 $120,000
Q2 2024 Aug 13, 2024	BUY	$7.78 - $14.19 $21,286 - $38,823	2,736 Added 45.98%	8,686 $69,000
Q1 2024 May 06, 2024	SELL	$7.59 - $17.47 $27,172 - $62,542	-3,580 Reduced 37.57%	5,950 $88,000
Q4 2023 Feb 09, 2024	BUY	$3.3 - $8.89 $2,158 - $5,814	654 Added 7.37%	9,530 $77,000
Q3 2023 Oct 27, 2023	BUY	$4.44 - $8.79 $12,067 - $23,891	2,718 Added 44.14%	8,876 $40,000
Q2 2023 Aug 11, 2023	BUY	$5.36 - $9.06 $10,371 - $17,531	1,935 Added 45.82%	6,158 $43,000
Q1 2023 May 05, 2023	BUY	$5.53 - $8.22 $17,507 - $26,024	3,166 Added 299.53%	4,223 $25,000
Q4 2022 Feb 10, 2023	BUY	$5.62 - $10.0 $1,309 - $2,330	233 Added 28.28%	1,057 $6,000
Q3 2022 Nov 01, 2022	BUY	$9.53 - $13.11 $3,135 - $4,313	329 Added 66.46%	824 $8,000
Q2 2022 Aug 03, 2022	BUY	$6.38 - $18.33 $1,473 - $4,234	231 Added 87.5%	495 $5,000
Q1 2022 May 13, 2022	BUY	$12.38 - $19.1 $3,268 - $5,042	264 New	264 $4,000

Others Institutions Holding IOVA

# of Institutions

314

Shares Held

241M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.46B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account